Evaluation of factors influencing antibody reduction for development of antibody drug conjugates

Meghdad, Abdollahpour Alitappeh; Majid, Lotfinia; Sepand, Razavi Vakhshourpour; Saeed, Jahandideh; Hamid, Najminejad; Koushan Sineh, Sepehr; Reza, Moazami; Elnaz, Shams; Mahdi, Habibi Anbouhi; Mohsen, Abolhassani

Meghdad, Abdollahpour Alitappeh; Majid, Lotfinia; Sepand, Razavi Vakhshourpour; Saeed, Jahandideh; Hamid, Najminejad; Koushan Sineh, Sepehr; Reza, Moazami; Elnaz, Shams; Mahdi, Habibi Anbouhi; Mohsen, Abolhassani.

IBJ-Iranian Biomedical Journal. 2017; 21 (4): 270-274

in English | IMEMR | ID: emr-189236

ABSTRACT

ABSTRACT

Background:

Reduction/alkylation is one of the leading strategies for the development of antibody drug conjugates [ADCs]. Precise control of the reduction process would not only yield a defined number of free thiols per antibody but also result in development of more homogenous conjugates

Subject(s)

Oxidation-Reduction; Pharmaceutical Preparations; Trastuzumab; Temperature; Sulfhydryl Compounds; Alkylation; Electrophoresis, Polyacrylamide Gel; Dithiothreitol

Search on Google

XML

Index: IMEMR (Eastern Mediterranean) Main subject: Oxidation-Reduction / Sulfhydryl Compounds / Temperature / Pharmaceutical Preparations / Dithiothreitol / Electrophoresis, Polyacrylamide Gel / Alkylation / Trastuzumab Language: English Journal: Iran. Biomed. J. Year: 2017

Similar

MEDLINE

LILACS

LIS

Search on Google

XML